A condition affecting 170 million women just got a new name, and doctors say the old one was misleading

An international team of medical professionals has renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), according to a study published in the journal The Lancet. The change follows 14 years of research to create a label that reflects the condition’s hormonal and metabolic drivers rather than the presence of “cysts,” which researchers clarify are actually follicles containing immature eggs.

Why was the name PCOS changed?

The previous label focused on the ovaries, but the condition’s effects are systemic. Helena Teede, an endocrinologist and director of the Monash Centre for Health Research and Implementation at Monash University in Australia, stated that scans show ordinary follicles rather than disease-causing growths. Teede noted there is “no increase in abnormal cysts on the ovary.”

The condition involves a hormone problem that extends beyond reproduction. Many patients experience insulin resistance, where cells stop responding to insulin and blood sugar increases. One study of young women found this increases the odds of developing type 2 diabetes.

How does PMOS affect the body and mind?

Patients often face symptoms that do not align with a name centered solely on ovaries. These include stubborn acne, unwanted hair growth, thinning hair, irregular periods, and difficulty conceiving.

Mental health is also significantly impacted. According to one paper, women with the condition have higher rates of anxiety and depression than those without it. This is attributed partly to the symptoms and partly to years of feeling dismissed by medical providers.

Will the new name improve diagnosis rates?

One review reports that as many as seven in 10 affected individuals are never diagnosed. Supporters of the name change argue that a label focused on ovaries hides other signs that doctors might otherwise investigate.

Currently, care is often splintered. A patient may visit different doctors for blood sugar, acne, and irregular periods without any single provider managing the whole picture. A clearer name may nudge the system toward coordinated care, which could result in fewer cases slipping past clinicians.

What happens next during the rollout?

The transition to PMOS will occur in stages over three years. This process involves updating medical guidelines, training providers, and revising the disease codes used by doctors.

Some clinicians question if a name change is the priority, citing thin research funding and spotty diagnosis as deeper problems. Others point to the cost and effort required to update textbooks, billing systems, and medical records.

For the roughly 170 million women living with the condition, the change may be invisible initially. However, it could allow researchers to pursue hormonal and metabolic roots more directly. A teenager with irregular periods and acne may, as a result, be checked for blood sugar issues sooner.

Frequently Asked Questions

What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome.

What is the difference between a cyst and a follicle in this context?

While the old name suggested cysts, the shapes seen on scans are actually follicles, which are tiny sacs that hold immature eggs.

How many women are affected by this condition?

Roughly 170 million women live with the condition.

How do you think a name change in medicine affects the way patients experience their care?